Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells

Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells

Chimeric antigen receptor (CAR) redirected T cells are potent therapeutic options against hematological malignancies. The current dominant manufacturing approach for CAR T cells depends on retroviral transduction. With the advent of gene editing, insertion of a CD19-CAR into the T cell receptor (TCR...

Full description

Bibliographic Details
Main Authors: Akyüz, L. (Author), Amini, L. (Author), Braun, T. (Author), Du, W. (Author), Höpken, U.E (Author), Jacobi, A.M (Author), Kath, J. (Author), Künkele, A. (Author), Kurgan, G.L (Author), Martini, S. (Author), Ostendorf, L. (Author), Pruene, A. (Author), Pruß, A. (Author), Rehm, A. (Author), Reinke, P. (Author), Schmueck-Henneresse, M. (Author), Stein, M. (Author), Stripecke, R. (Author), Sturgeon, M.L (Author), Thommandru, B. (Author), Turk, R. (Author), Volk, H.-D (Author), Wagner, D.L (Author), Wilhelm, A. (Author), Zittel, T. (Author)
Format: Article
Language:English
Published: Cell Press 2022
Subjects:
adoptive T cell therapy
CAR T cells
chimeric antigen receptor
CRISPR-Cas9
gene editing
HDR
knockin
non-viral cell manufacturing
TRAC
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items